p53 functions and cell lines: Have we learned the lessons from the past?

BioEssays

Volumn 32, Issue 5, 2010, Pages 392-400

  Millau, Jean François ^a   Mai, Sabine ^b   Bastien, Nathalie ^a   Drouin, Régen ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cancer; Cell lines; Limitations; p53

Indexed keywords

PROTEIN P53;

CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL DIVISION; CELL IMMORTALIZATION; CELL LINE; CELL STRUCTURE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; NONHUMAN; PHENOTYPE; REVIEW;

EID: 77951751797     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.200900160     Document Type: Review

References (75)

1. Linzer DI, Levine AJ. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52. (Pubitemid 9188209)
2. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263
3. DeLeo AB, Jay G, Appella E, et al. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76: 2420-2424 (Pubitemid 9185501)
4. Baker SJ, Fearon ER, Nigro JM, et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221
5. Jay G, Khoury G, DeLeo AB, et al. 1981. p53 transformation-related protein: detection of an associated phosphotransferase activity. Proc Natl Acad Sci U S A 78: 2932-2936 (Pubitemid 11114249)
6. Mowat M, Cheng A, Kimura N, et al. 1985. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314: 633-636 (Pubitemid 15080842)
7. Nedelcu AM, Tan C. 2007. Early diversification and complex evolutionary history of the p53 tumor suppressor gene family. Dev Genes Evol 217: 801-806 (Pubitemid 350245965)
8. Levine AJ. 2009. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384: 285-293
9. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310
10. Vousden KH, Lu X. 2002. Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604. (Pubitemid 37328926)
11. Wei CL, Wu Q, Vega VB, et al. 2006. A global map of p53 transcriptionfactor binding sites in the human genome. Cell 124: 207-219 (Pubitemid 43069320)
12. Hwang BJ, Ford JM, Hanawalt PC, et al. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A 96: 424-428
13. Hussain SP, Amstad P, He P, et al. 2004. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 64: 2350-2356 (Pubitemid 38523887)
14. Thornborrow EC, Patel S, Mastropietro AE, et al. 2002. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 21: 990-999 (Pubitemid 34174511)
15. Wang P, Yu J, Zhang L. 2007. The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci U S A 104: 4054-4059 (Pubitemid 47181577)
16. el-Deiry WS, Tokino T, Waldman T, et al. 1995. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919
17. Feng Z, Zhang H, Levine AJ, et al. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102: 8204-8209 (Pubitemid 40800067)
18. Matoba S, Kang JG, PatinoWD, et al. 2006. p53 regulates mitochondrial respiration. Science 312: 1650-1653
19. Bensaad K, Tsuruta A, Selak MA, et al. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120 (Pubitemid 44040989)
20. Corney DC, Flesken-Nikitin A, Godwin AK, et al. 2007. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433-8438 (Pubitemid 47437414)
21. Murray-Zmijewski F, Slee EA, Lu X. 2008. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9: 702-712
22. Millau JF, Bastien N, Drouin R. 2009. P53 transcriptional activities: a general overview and some thoughts. Mutat Res 681: 118-133
23. Olivier M, Eeles R, Hollstein M, et al. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614 (Pubitemid 34556481)
24. Hayflick L, Moorhead PS. 1961. The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585-621.
25. Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460 (Pubitemid 20178256)
26. Shay JW, Wright WE. 1989. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res 184: 109-118
27. Wei W, Sedivy JM. 1999. Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res 253: 519-522 (Pubitemid 30003113)
28. Counter CM, Hahn WC, Wei W, et al. 1998. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95: 14723-14728 (Pubitemid 29003697)
29. O'Connor PM, Jackman J, Bae I, et al. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300 (Pubitemid 27413438)
30. Fan S, Cherney B, Reinhold W, et al. 1998. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047-1054 (Pubitemid 28183408)
31. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923 (Pubitemid 44862676)
32. Sherr CJ. 2006. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673
33. DiTullio RA, Jr., Mochan TA, Venere M, et al. 2002. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 4: 998-1002. (Pubitemid 35469432)
34. Brummelkamp TR, Fabius AW, Mullenders J, et al. 2006. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2: 202-206
35. Sedelnikova OA, Horikawa I, Zimonjic DB, et al. 2004. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 6: 168-170 (Pubitemid 38425717)
36. Ponten J, Saksela E. 1967. Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer 2: 434-447
37. Soule HD, Vazguez J, Long A, et al. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416
38. Brattain MG, Fine WD, Khaled FM, et al. 1981. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756 (Pubitemid 11114567)
39. Dunn KL, He S, Wark L, et al. 2009. Increased genomic instability and altered chromosomal protein phosphorylation timing in HRAS-transformed mouse fibroblasts. Genes Chromosomes Cancer 48: 397-409.
40. Olsson A, Manzl C, Strasser A, et al. 2007. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14: 1561-1575
41. Oda K, Arakawa H, Tanaka T, et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862
42. Knights CD, Catania J, Di Giovanni S, et al. 2006. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173: 533-544 (Pubitemid 43765200)
43. Flores ER, Tsai KY, Crowley D, et al. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564 (Pubitemid 34288861)
44. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781-794 (Pubitemid 33030212)
45. Weinberg RL, Veprintsev DB, Bycroft M, et al. 2005. Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 348: 589-596 (Pubitemid 40515671)
46. Espinosa JM. 2008. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27: 4013-4023
47. Espinosa JM, Verdun RE, Emerson BM. 2003. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12: 1015-1027
48. Donner AJ, Szostek S, Hoover JM, et al. 2007. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell 27: 121-133 (Pubitemid 46991381)
49. Shaked H, Shiff I, Kott-Gutkowski M, et al. 2008. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res 68: 9671-9677
50. Millau JF, Bastien N, Bouchard EF, et al. 2009. p53 Pre- and post-binding event theories revisited: stresses reveal specific and dynamic p53-binding patterns on the p21 gene promoter. Cancer Res 69: 8463-8471
51. Tergaonkar V, Perkins ND. 2007. p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol Cell 26: 158-159 (Pubitemid 46617342)
52. Webster GA, Perkins ND. 1999. Transcriptional cross talk between NFkappaB and p53. Mol Cell Biol 19: 3485-3495
53. Nesic D, Grumont R, Gerondakis S. 2008. The nuclear factor-kappaB and p53 pathways function independently in primary cells and transformed fibroblasts responding to genotoxic damage. Mol Cancer Res 6: 1193-1203
54. Roperch JP, Lethrone F, Prieur S, et al. 1999. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). Proc Natl Acad Sci U S A 96: 8070-8073 (Pubitemid 29328409)
55. Relaix F, Wei X, Li W, et al. 2000. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci U S A 97: 2105-2110 (Pubitemid 30134029)
56. Frew IJ, Dickins RA, Cuddihy AR, et al. 2002. Normal p53 function in primary cells deficient for Siah genes. Mol Cell Biol 22: 8155-8164 (Pubitemid 35304049)
57. Masters JR. 2000. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 1: 233-236
58. Hughes P, Marshall D, Reid Y, et al. 2007. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 43: 575, 577-8, 581-582 passim.
59. Masters JR. 2002. False cell lines: the problem and a solution. Cytotechnology 39: 69-74.
60. Berglind H, Pawitan Y, Kato S, et al. 2008. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7: 699-708. (Pubitemid 351847005)
61. Lacroix M. 2008. Persistent use of "false" cell lines. Int J Cancer 122: 1-4.
62. Miller CJ, Kassem HS, Pepper SD, et al. 2003. Mycoplasma infection significantly alters microarray gene expression profiles. Biotechniques 35: 812-814 (Pubitemid 37248366)
63. Cimolai N. 2001. Do mycoplasmas cause human cancer? Can J Microbiol 47: 691-697
64. Logunov DY, Scheblyakov DV, Zubkova OV, et al. 2008. Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene 27: 4521-4531
65. Halliwell B. 2003. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 540: 3-6.
66. Saferali A, Grundberg E, Berlivet S, et al. Cell culture-induced aberrant methylation of the imprinted IG DMR in human lymphoblastoid cell lines. Epigenetics 5.
67. 2000. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer 82: 1495-1509 (Pubitemid 30204353)
68. Donehower LA, Harvey M, Slagle BL, et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
69. Attardi LD, Donehower LA. 2005. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 576: 4-21.
70. Fukasawa K, Choi T, Kuriyama R, et al. 1996. Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747 (Pubitemid 26102826)
71. Fukasawa K, Wiener F, Vande Woude GF, et al. 1997. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15: 1295-1302 (Pubitemid 27429745)
72. Pan C, Kumar C, Bohl S, et al. 2009. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell typespecific functions. Mol Cell Proteomics 8: 443-450
73. Wilkening S, Stahl F, Bader A. 2003. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotrans-formation properties. Drug Metab Dispos 31: 1035-1042 (Pubitemid 36975674)
74. Lidington EA, Moyes DL, McCormack AM, et al. 1999. A comparison of primary endothelial cells and endothelial cell lines for studies of immune interactions. Transpl Immunol 7: 239-246
75. Lacoste S, Wiechec E, Dos Santos Silva AG, et al. 2010. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 29: 503-515